AB&B BIO-TECH-B (02627) Initiates Phase III Clinical Trial for Freeze-Dried Human Rabies Vaccine (HDCV)

Stock News12-08

AB&B BIO-TECH-B (02627) announced the initiation of a Phase III clinical trial for its freeze-dried human rabies vaccine (HDCV). The investigational vaccine targets three immunization regimens. In November 2022, the company received approval from China's National Medical Products Administration for clinical trials of the Essen (5-dose) regimen, followed by supplementary approvals for the Zagreb (4-dose) and simplified 4-dose regimens in April 2023. The Phase I clinical trial for this vaccine candidate was completed in October 2024.

Rabies is a severe viral disease caused by the rabies virus, which can lead to symptoms such as confusion and progressive paralysis. Once symptoms appear, the disease is almost invariably fatal, but timely vaccination post-exposure can prevent infection. The HDCV rabies vaccine, developed using human diploid cells, is recognized by the World Health Organization as the "gold standard" due to its strong safety profile. The company's investigational vaccine has demonstrated favorable safety characteristics in the completed Phase I trial.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1148973954?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 17:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1148973954","market":"sh","top_or_hot":-1,"title":"AB&B BIO-TECH-B (02627) Initiates Phase III Clinical Trial for Freeze-Dried Human Rabies Vaccine (HDCV)","media":"Stock News","content":"<p>AB&B BIO-TECH-B (02627) announced the initiation of a Phase III clinical trial for its freeze-dried human rabies vaccine (HDCV). The investigational vaccine targets three immunization regimens. In November 2022, the company received approval from China's National Medical Products Administration for clinical trials of the Essen (5-dose) regimen, followed by supplementary approvals for the Zagreb (4-dose) and simplified 4-dose regimens in April 2023. The Phase I clinical trial for this vaccine candidate was completed in October 2024.</p>\n<p>Rabies is a severe viral disease caused by the rabies virus, which can lead to symptoms such as confusion and progressive paralysis. Once symptoms appear, the disease is almost invariably fatal, but timely vaccination post-exposure can prevent infection. The HDCV rabies vaccine, developed using human diploid cells, is recognized by the World Health Organization as the \"gold standard\" due to its strong safety profile. The company's investigational vaccine has demonstrated favorable safety characteristics in the completed Phase I trial.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AB&B BIO-TECH-B (02627) Initiates Phase III Clinical Trial for Freeze-Dried Human Rabies Vaccine (HDCV)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAB&B BIO-TECH-B (02627) Initiates Phase III Clinical Trial for Freeze-Dried Human Rabies Vaccine (HDCV)\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-08 17:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>AB&B BIO-TECH-B (02627) announced the initiation of a Phase III clinical trial for its freeze-dried human rabies vaccine (HDCV). The investigational vaccine targets three immunization regimens. In November 2022, the company received approval from China's National Medical Products Administration for clinical trials of the Essen (5-dose) regimen, followed by supplementary approvals for the Zagreb (4-dose) and simplified 4-dose regimens in April 2023. The Phase I clinical trial for this vaccine candidate was completed in October 2024.</p>\n<p>Rabies is a severe viral disease caused by the rabies virus, which can lead to symptoms such as confusion and progressive paralysis. Once symptoms appear, the disease is almost invariably fatal, but timely vaccination post-exposure can prevent infection. The HDCV rabies vaccine, developed using human diploid cells, is recognized by the World Health Organization as the \"gold standard\" due to its strong safety profile. The company's investigational vaccine has demonstrated favorable safety characteristics in the completed Phase I trial.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"159646","symbol_name":"疫苗","start_time":0,"source_url":"","article_id":"1148973954","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1148973954","pubTimestamp":1765185513,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"AB&B BIO-TECH-B (02627) announced the initiation of a Phase III clinical trial for its freeze-dried human rabies vaccine (HDCV). The investigational vaccine targets three immunization regimens. In...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159646":"疫苗","III":"信息服务","BK1161":"生物科技","02627":"中慧生物-B","BK4134":"信息科技咨询与其它服务"},"translate_title":"AB&B生物-B(02627)启动冻干人用狂犬病疫苗(HDCV)III期临床试验","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159646":1,"02627":1,"III":1},"content_text":"AB&B BIO-TECH-B (02627) announced the initiation of a Phase III clinical trial for its freeze-dried human rabies vaccine (HDCV). The investigational vaccine targets three immunization regimens. In November 2022, the company received approval from China's National Medical Products Administration for clinical trials of the Essen (5-dose) regimen, followed by supplementary approvals for the Zagreb (4-dose) and simplified 4-dose regimens in April 2023. The Phase I clinical trial for this vaccine candidate was completed in October 2024.\nRabies is a severe viral disease caused by the rabies virus, which can lead to symptoms such as confusion and progressive paralysis. Once symptoms appear, the disease is almost invariably fatal, but timely vaccination post-exposure can prevent infection. The HDCV rabies vaccine, developed using human diploid cells, is recognized by the World Health Organization as the \"gold standard\" due to its strong safety profile. The company's investigational vaccine has demonstrated favorable safety characteristics in the completed Phase I trial.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1148973954","isCrawlerRequest":true}